
Adaptive Biotechnologies announced that its clonoSEQ test for measurable residual disease (MRD) will be highlighted in about 100 abstracts at the 68th Annual Meeting of the American Society of Hematology (ASH) in December 2026. The test plays a key role in assessing treatment response and guiding therapy in blood cancers like multiple myeloma, chronic lymphocytic leukemia, and lymphoma. Studies presented will show how clonoSEQ helps tailor treatments, evaluate drug efficacy, and improve patient outcomes, reinforcing its clinical and real-world value. This showcases the growing importance of MRD-guided care in hematology and Adaptive's leadership in this field.
Adaptive Biotechnologies trades with a market cap of $4.51 billion and a daily volume of 2,644,255 shares on Pluang as of Nov 18, 2026, 15:11 WIB. The stock price is currently USD 28.49, up 2.22% on the day. This trading activity highlights investor interest in the company as it showcases its clonoSEQ test's role in advancing MRD-guided care in hematology at ASH 2026.